Candel Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Candel Therapeutics

10/08/2026 14:39

Candel Therapeutics Inc CADL.OQ CADL.O is expected to  show no change in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Candel Therapeutics Inc is for a loss of 24 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Candel Therapeutics Inc is $22.50, about 112.5% above its last closing price of $10.59
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.33
-0.32
-0.14
Beat
55.8
Dec. 31 2026
-0.24
-0.25
-0.54
Missed
-119.6
Sep. 30 2025
-0.20
-0.19
-0.21
Missed
-13.4​
Jun. 30 2025
-0.17
-0.17
-0.09
Beat
47.1
​​Mar. 31 2025
-0.31
-0.30
0.13
Beat
143.3
Dec. 31 2024
-0.22
-0.23
-0.40
Missed
-75.8​
This summary was machine generated August 10 at 13:39 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)